ESSA Pharma 2021 Investor Presentation - EPI-7386 Clinical Development

ESSA Pharma is a clinical-stage biopharmaceutical company developing first-in-class N-terminal domain inhibitors of the androgen receptor for treatment-resistant prostate cancer and other hormone-driven malignancies. The company's lead candidate EPI-7386 entered Phase 1 studies in 2020, with development initially focused on resistant metastatic castration-resistant prostate cancer.